Immunofluorescence Assay for Serologic Diagnosis of SARS

Chan, Paul K.S.; Ng, King-Cheung; Chan, RW; Lam, Robert F.; Chow, Viola Chi Ying; Hui, Mamie; Wu, Andi; Lee, Nelson; Yap, Florence; Cheng, Frankie Wai Tsoi; Sung, Joseph J.Y.; Tam, John S.

doi:10.3201/eid1003.030493

Cited by 60 publications

(54 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3,4 Briefly, uncertainty regarding the true value of the Se and Sp of the test and the disease prevalence (p) was modeled using probability distributions referred to as prior distributions. Prior values for the cELISA, based on the uncertainty for the Se and Sp values, were modeled using data reported in peer-reviewed literature [9][10][11]15,27 and at professional conferences (Rigoni M, Viale E, Mancin M, et al: 2009, Development of a competitive ELISA system for the detection of influenza A virus nucleoprotein antibodies and validation in five species of poultry. In: Proceedings of the World Association of Veterinary Laboratory Diagnosticians 14th International Symposium, p. 174.…”

Section: Methodsmentioning

confidence: 99%

A Diagnostic Algorithm for Detection of Antibodies to Influenza A Viruses in Dogs in Italy (2006–2008)

Benedictis

Anderson²,

Pérez

et al. 2010

J VET Diagn Invest

View full text Add to dashboard Cite

Abstract. Since 2004, there have been several reports of Influenza A virus (FLUAV) infection in dogs. Dogs have been infected with equine influenza H3N8, avian influenza H3N2 and H5N1, and the pandemic H1N1 virus. Because of recent avian and equine influenza outbreaks in Italy, the objectives of the present study were to estimate the level of exposure of Italian dogs to influenza A viruses and to assess a diagnostic algorithm for detection of FLUAV exposure in dogs. Sera collected from 6,858 dogs from 2006 to 2008 were screened in a competitive enzyme-linked immunosorbent assay (cELISA) for antibodies to the highly conserved influenza A nucleoprotein. Samples positive in the cELISA were confirmed by testing in hemagglutination inhibition (HI) and fluorescent antibody test (FAT). Two seropositive dogs had antibodies to H3 hemagglutinin proteins, consistent with exposure to recent canine and equine subtype H3N8 viruses. Using a Bayesian model, the sensitivity and specificity of the cELISA were estimated as 93.98% (probability intervals [PI]: 81.67-99.08%) and 98.71% (PI: 98.43-98.96%), respectively. After accounting for the imperfect sensitivity and specificity of the cELISA, the Bayesian posterior prevalence of FLUAV exposure among tested Italian dogs was 0.5% (PI: 0.1-1.4%). The study results indicate that screening with a cELISA for influenza A nucleoprotein antibody, followed by confirmatory testing with HI and/or FAT, is a highly sensitive and highly specific approach for diagnosing FLUAV exposure in dogs.

show abstract

Section: Methodsmentioning

confidence: 99%

A Diagnostic Algorithm for Detection of Antibodies to Influenza A Viruses in Dogs in Italy (2006–2008)

Benedictis

Anderson²,

Pérez

et al. 2010

J VET Diagn Invest

View full text Add to dashboard Cite

show abstract

“…10 Previous studies demonstrated that 93% of SARS patients seroconverted by 4 weeks, 11 and 100% seroconverted by 35 days after onset of illness. 12 Also, none of the 2400 healthy blood donor sera were seropositive for SARS-coronavirus when tested by IFA, indicating a specificity of 100%. 13 The antibody level remained constant up to 7 months after infection.…”

Section: Laboratory Analysismentioning

confidence: 98%

Risk-Stratified Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus Among Children in Hong Kong

Lee¹,

Wong²,

Leung

et al. 2006

Pediatrics

View full text Add to dashboard Cite

show abstract

“…SARS coronavirus (SARS-CoV) is the responsible agent and was transmitted from wild animals to the human population [54,55], and delayed identification of this virus aided contagion. The SARS virus is detected in humans by RT-PCR [56,57] indirect fluorescence assay, which detects anti-SARS-CoV antibodies in body fluids [58] and by isolation of SARS-CoV from clinical samples [59,60]. Such viral culturing is time consuming, tedious and insensitive, therefore, PCR-and antibody-based detection methods are the predominant techniques adopted for surveillance.…”

Section: Reviewmentioning

confidence: 99%

A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications

Byrne

Conroy

Whisstock

et al. 2013

Trends in Biotechnology

147

View full text Add to dashboard Cite

Artificial manipulation of antibody genes has facilitated the production of several unique recombinant antibody formats, which have highly important therapeutic and biotechnological applications. Although bispecific antibodies (bsAbs) are not new, they are coming to the forefront as our knowledge of the potential efficacy of antibody-based therapeutics expands. The next generation of bsAbs is developing due to significant improvements in recombinant antibody technologies. This review focuses on recent advances with a particular focus on improvements in format and design that are contributing to the resurgence of bsAbs, and in particular, on innovative structures applicable to next generation point-of-care (POC) devices with applicability to low resource environments.

show abstract

Immunofluorescence Assay for Serologic Diagnosis of SARS

Cited by 60 publications

References 7 publications

A Diagnostic Algorithm for Detection of Antibodies to Influenza A Viruses in Dogs in Italy (2006–2008)

A Diagnostic Algorithm for Detection of Antibodies to Influenza A Viruses in Dogs in Italy (2006–2008)

Risk-Stratified Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus Among Children in Hong Kong

A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications

Contact Info

Product

Resources

About